Ivermectin is a broad‑spectrum antiparasitic medication used worldwide in both oral and topical formulations. Oral ivermectin is primarily indicated for systemic parasitic infections such as scabies, strongyloidiasis, onchocerciasis, and resistant lice infestations. Topical ivermectin, including branded Soolantra cream, is widely used in dermatology for inflammatory rosacea and Demodex‑associated skin conditions. Its mechanism of action is based on selective binding to parasite chloride channels, leading to paralysis and elimination while maintaining a strong safety margin in humans.
This pillar page provides a complete scientific overview of ivermectin, covering pharmacology, clinical indications, safety, formulation differences, and evidence‑based therapeutic use. Explore detailed subpages on Ivermectin oral, Ivermectin topical, and Soolantra cream to understand how each form is used in modern clinical practice. Whether for systemic parasitic infections or dermatologic conditions, ivermectin remains one of the most versatile antiparasitic agents available.
Ivermectin is a broad‑spectrum antiparasitic medication from the macrocyclic lactone class, originally derived from avermectins produced by the soil microorganism Streptomyces avermitilis. Its discovery marked a major breakthrough in parasitology, leading to widespread global use in both community‑level disease control programs and individual clinical treatment. Ivermectin selectively targets parasite chloride channels, causing paralysis and death while maintaining a strong safety margin in humans due to limited penetration into the central nervous system.
The drug is available in several formulations, each designed for specific therapeutic needs. Oral ivermectin tablets are used for systemic parasitic infections such as scabies, strongyloidiasis, onchocerciasis, and resistant lice infestations. Topical formulations—including creams, lotions, and gels—are widely used in dermatology for inflammatory rosacea and Demodex‑associated skin disorders. Branded products include Stromectol (oral ivermectin) and Soolantra (ivermectin 1% cream), both of which remain central to modern antiparasitic and dermatologic therapy. This page provides a complete overview of ivermectin’s origin, pharmacology, clinical uses, and formulation differences.
| Form | Concentration | Route | Main Indications | Internal Link |
|---|---|---|---|---|
| Oral tablets | 3 mg, 6 mg | Oral | Scabies, strongyloidiasis, onchocerciasis, lice | Ivermectin 3 mg |
| Cream | 1% | Topical | Rosacea, Demodex overgrowth | Ivermectin cream 1% |
| Lotion | Varies | Topical | Lice, mite‑related irritation | Ivermectin topical |
| Gel | 1% | Topical | Rosacea, inflammatory lesions | Soolantra cream |
Ivermectin exerts its antiparasitic activity through a highly selective mechanism involving glutamate‑gated chloride channels, which are present in the nerve and muscle cells of many invertebrates but absent in humans. When ivermectin binds to these channels, it increases the influx of chloride ions, causing hyperpolarization of the parasite’s neuromuscular system. This leads to flaccid paralysis, immobilization, and ultimately death of the parasite. The drug’s safety in humans is largely due to the blood–brain barrier, which prevents ivermectin from reaching mammalian GABA‑mediated neural pathways.
In addition to its systemic antiparasitic effects, ivermectin demonstrates clinically meaningful anti‑inflammatory properties when applied topically. In rosacea, topical ivermectin reduces inflammatory lesions by decreasing neutrophil activation, lowering pro‑inflammatory cytokine production, and reducing the density of Demodex mites, which are believed to contribute to inflammation in susceptible individuals. This dual mechanism—paralysis of parasites and modulation of inflammatory pathways—explains why ivermectin is effective across both systemic infections and dermatologic conditions. A more detailed scientific explanation is available on the dedicated page: Ivermectin MOA.
| Form | Primary Mechanism | Target Tissues | Clinical Focus |
|---|---|---|---|
| Oral Ivermectin | Activation of glutamate‑gated chloride channels causing systemic parasite paralysis | Bloodstream, tissues affected by nematodes and ectoparasites | Scabies, strongyloidiasis, onchocerciasis, resistant lice |
| Topical Ivermectin | Anti‑inflammatory action plus reduction of Demodex density | Skin, pilosebaceous units | Rosacea, Demodex‑associated irritation, inflammatory lesions |
The pharmacokinetics of ivermectin differ significantly between oral and topical formulations, but both share the same fundamental metabolic pathways. After oral administration, ivermectin is absorbed in the gastrointestinal tract with enhanced uptake when taken with a fatty meal. Peak plasma concentrations are typically reached within 4–5 hours. Due to its high lipophilicity, ivermectin distributes widely into tissues, particularly those with high fat content, which contributes to its prolonged activity and slow elimination.
Distribution is characterized by strong binding to plasma proteins, primarily albumin, which helps maintain stable systemic levels. Metabolism occurs mainly in the liver via the CYP3A4 enzyme system, producing several inactive metabolites. This pathway is clinically relevant because co‑administration with CYP3A4 inhibitors may increase systemic exposure. Elimination is primarily fecal, with less than 1% excreted in urine. The terminal half‑life ranges from 12 to 36 hours depending on the dose, formulation, and patient physiology.
Topical ivermectin demonstrates minimal systemic absorption, making it suitable for chronic dermatologic use. Plasma concentrations remain extremely low, and systemic side effects are rare. Despite low absorption, topical ivermectin achieves high local concentrations in the skin and pilosebaceous units, enabling both anti‑parasitic and anti‑inflammatory effects. More detailed pharmacokinetic data can be found on the dedicated page: Ivermectin PK.
| Parameter | Oral Ivermectin | Topical Ivermectin |
|---|---|---|
| Absorption | High; increased with fatty meals | Minimal systemic absorption |
| Distribution | Wide tissue distribution; high lipophilicity | Localized to skin and follicles |
| Metabolism | Hepatic via CYP3A4 | Negligible systemic metabolism |
| Elimination | Primarily fecal; <1% renal | Minimal systemic elimination |
Ivermectin is available in multiple pharmaceutical forms designed to treat a wide range of systemic and dermatologic conditions. The most common oral formulations include 3 mg and 6 mg tablets, which are used for parasitic infections such as scabies, strongyloidiasis, onchocerciasis, and resistant lice infestations. These tablets provide predictable systemic exposure and are typically administered as single‑dose or short‑course regimens depending on the indication.
Topical ivermectin is formulated as 1% cream, lotion, or gel. These preparations are primarily used in dermatology for inflammatory rosacea, Demodex overgrowth, and certain forms of acne or perioral dermatitis. The 1% cream formulation is the most widely studied and is the basis of the branded product Soolantra. Topical forms deliver high local concentrations with minimal systemic absorption, making them suitable for long‑term use.
Branded ivermectin products include Stromectol (oral ivermectin tablets) and Soolantra (ivermectin 1% cream). Stromectol is widely used in global parasitic disease control programs, while Soolantra is a leading dermatologic therapy for rosacea. Generic versions of both oral and topical ivermectin are available in many regions, offering cost‑effective alternatives without compromising efficacy.
| Form | Concentration | Route | Primary Use | Example |
|---|---|---|---|---|
| Oral tablet | 3 mg, 6 mg | Oral | Systemic parasitic infections | Stromectol |
| Cream | 1% | Topical | Rosacea, Demodex | Soolantra |
| Lotion | Varies | Topical | Lice, mite‑related irritation | Generic ivermectin lotion |
| Gel | 1% | Topical | Rosacea, inflammatory lesions | Generic ivermectin gel |
Ivermectin is approved and widely used for a broad range of parasitic and dermatologic conditions. Its dual mechanism—paralysis of parasites and anti‑inflammatory activity—allows it to function across systemic infections and chronic inflammatory skin disorders. The drug is available in oral and topical forms, each optimized for specific clinical scenarios. Oral ivermectin is primarily used for systemic parasitic infections, while topical ivermectin is preferred for dermatologic conditions such as rosacea and Demodex‑associated inflammation.
Oral ivermectin is a first‑line therapy for several parasitic diseases. In scabies, it is used when topical treatments fail, when infestations are severe (such as crusted scabies), or when large‑scale outbreaks require systemic therapy. Ivermectin for scabies is typically administered as a single dose with a repeat dose after one week. For strongyloidiasis, ivermectin is considered the treatment of choice due to its high efficacy and favorable safety profile. It is especially important in patients at risk of hyperinfection syndrome, where early systemic therapy is critical. Ivermectin is also used for lice infestations, particularly in cases resistant to topical pediculicides. Its systemic action helps eliminate lice and nits that survive topical treatments.
Additional parasitic indications include onchocerciasis, where ivermectin reduces microfilarial load and prevents disease progression. It is also used in mass drug administration programs in endemic regions due to its long‑lasting antiparasitic effect and ease of dosing.
Topical ivermectin plays a major role in dermatology, particularly for inflammatory rosacea. Its anti‑inflammatory properties help reduce papules, pustules, and erythema, while its anti‑parasitic activity lowers Demodex mite density, which is believed to contribute to inflammation in susceptible individuals. Ivermectin for rosacea is typically applied once daily and is well tolerated for long‑term use.
Ivermectin is also used for Demodex‑associated skin disorders, including Demodex folliculitis and certain forms of acne where mite overgrowth plays a role. In perioral dermatitis, topical ivermectin may be used as an alternative to topical antibiotics or anti‑inflammatory agents, especially when Demodex involvement is suspected. Its ability to reduce inflammation while targeting mites makes it a versatile option in dermatologic therapy.
Together, these indications highlight ivermectin’s unique position as both a systemic antiparasitic agent and a targeted dermatologic therapy. More detailed information is available on dedicated pages such as Ivermectin for scabies, Ivermectin for strongyloides, Ivermectin for lice, Ivermectin for rosacea, and Ivermectin for demodex.
| Form | Primary Indications | Clinical Focus | Typical Use |
|---|---|---|---|
| Oral Ivermectin | Scabies, strongyloidiasis, onchocerciasis, lice | Systemic parasitic infections | Single‑dose or short‑course therapy |
| Topical Ivermectin | Rosacea, Demodex overgrowth, inflammatory lesions | Dermatology and chronic skin conditions | Daily long‑term application |
Oral ivermectin, widely known under the brand name Stromectol, is a systemic antiparasitic medication used for the treatment of a broad range of internal parasitic infections. It is most commonly prescribed for scabies, strongyloidiasis, onchocerciasis, and resistant lice infestations. Due to its predictable pharmacokinetics, strong safety profile, and ease of administration, oral ivermectin is considered a cornerstone therapy in both individual clinical practice and large‑scale public health programs.
Oral ivermectin is typically administered as a single dose or short‑course regimen, depending on the indication. Its mechanism of action involves binding to glutamate‑gated chloride channels in invertebrate nerve and muscle cells, leading to paralysis and death of the parasite. Because these channels are absent in humans and the drug has limited penetration into the central nervous system, oral ivermectin maintains a wide therapeutic margin.
The advantages of oral ivermectin include rapid onset of action, high efficacy against a variety of parasites, and convenience of dosing. It is especially valuable in cases where topical treatments are impractical, such as crusted scabies, widespread infestations, or institutional outbreaks. However, oral ivermectin also has limitations. It may be less effective in patients with compromised immune systems, and repeated dosing may be required for certain infections. Additionally, its metabolism via CYP3A4 means that drug interactions can occur with medications that inhibit or induce this enzyme.
Stromectol remains the most recognized branded formulation of oral ivermectin, although generic versions are widely available. Pricing varies by region, and cost considerations may influence treatment decisions. More detailed information is available on the dedicated pages: Ivermectin oral and Stromectol price.
| Parameter | Description |
|---|---|
| Form | Oral tablets (3 mg, 6 mg) |
| Primary Uses | Scabies, strongyloidiasis, onchocerciasis, lice |
| Dosing | Single dose or short‑course therapy depending on indication |
| Advantages | Rapid onset, systemic coverage, high efficacy |
| Limitations | Potential need for repeat dosing; reduced efficacy in immunocompromised patients |
| Metabolism | Hepatic via CYP3A4 |
| Drug Interactions | CYP3A4 inhibitors/inducers may alter systemic exposure |
| Brand Example | Stromectol |
Topical ivermectin is a dermatologic formulation of the macrocyclic lactone antiparasitic agent designed for localized treatment of inflammatory skin conditions. Unlike oral ivermectin, which provides systemic coverage for internal parasitic infections, topical ivermectin delivers high local concentrations directly to the skin and pilosebaceous units with minimal systemic absorption. This makes it particularly suitable for chronic dermatologic use, where long‑term safety and targeted anti‑inflammatory effects are essential.
The most widely used topical formulation is ivermectin 1% cream, which is the basis of the branded product Soolantra. This cream is approved for the treatment of inflammatory rosacea, where it reduces papules, pustules, and erythema through a combination of anti‑parasitic and anti‑inflammatory mechanisms. By lowering Demodex mite density and suppressing inflammatory cytokines, topical ivermectin addresses both the microbial and inflammatory components of rosacea. It is typically applied once daily and is well tolerated even with prolonged use.
In addition to the 1% cream, topical ivermectin is available in lotion and gel formulations. These variations allow clinicians to tailor treatment to different skin types and conditions. Lotions are often preferred for larger surface areas or hair‑bearing regions, while gels may be used for patients who prefer lighter, fast‑absorbing textures. Although not all formulations are approved for every indication, they are commonly used off‑label for Demodex folliculitis, certain acne variants, and perioral dermatitis when mite overgrowth or inflammation is suspected.
Topical ivermectin offers several advantages: minimal systemic exposure, strong anti‑inflammatory activity, and excellent tolerability. Limitations include slower onset compared to some topical antibiotics and the need for consistent daily application. More detailed information is available on the dedicated pages: Ivermectin topical and Ivermectin cream 1%.
| Form | Concentration | Texture / Vehicle | Primary Indications | Example |
|---|---|---|---|---|
| Cream | 1% | Rich, moisturizing | Rosacea, Demodex overgrowth | Soolantra |
| Lotion | Varies | Light, spreadable | Lice, mite‑related irritation | Generic ivermectin lotion |
| Gel | 1% | Lightweight, fast‑absorbing | Rosacea, inflammatory lesions | Generic ivermectin gel |
Soolantra is a branded topical formulation of ivermectin 1% cream developed specifically for the treatment of inflammatory rosacea. It represents one of the most advanced dermatologic applications of ivermectin, combining anti‑parasitic and anti‑inflammatory mechanisms in a single, well‑tolerated topical therapy. The formulation is designed to deliver high local concentrations of ivermectin to the skin and pilosebaceous units while maintaining minimal systemic absorption, making it suitable for long‑term daily use.
The active ingredient in Soolantra is ivermectin, a macrocyclic lactone originally derived from avermectins produced by Streptomyces avermitilis. While generic ivermectin creams also contain the same active molecule, Soolantra differs in its vehicle composition, stability profile, and optimized dermal penetration. These formulation characteristics contribute to improved skin tolerability and consistent delivery of the active ingredient, which may enhance clinical outcomes in patients with rosacea.
Soolantra is primarily indicated for the treatment of papulopustular rosacea, where it reduces inflammatory lesions, erythema, and skin sensitivity. Its dual mechanism includes suppression of inflammatory cytokines and reduction of Demodex mite density, both of which are believed to play a role in rosacea pathophysiology. Clinical studies have shown that Soolantra can produce visible improvements within several weeks, with continued benefits during long‑term therapy.
Compared to generic ivermectin formulations, Soolantra offers a more refined vehicle, smoother application, and enhanced cosmetic acceptability. However, cost may be a limiting factor for some patients, as branded products are typically more expensive. Additional details can be found on the dedicated pages: Soolantra vs Ivermectin and Soolantra price.
| Parameter | Description |
|---|---|
| Active Ingredient | Ivermectin 1% |
| Formulation | Topical cream with optimized dermal penetration |
| Primary Indication | Papulopustular rosacea |
| Mechanism | Anti‑inflammatory action and reduction of Demodex density |
| Advantages | High tolerability, minimal systemic absorption, once‑daily use |
| Comparison to Generic | More refined vehicle and improved cosmetic profile |
| Brand‑Specific Pages | Soolantra vs Ivermectin, Soolantra price |
Ivermectin is frequently compared with other antiparasitic and dermatologic agents due to its dual mechanism of action, broad clinical utility, and availability in both oral and topical forms. Below are key comparisons that highlight differences in mechanism, indications, and clinical use. More detailed information is available on dedicated pages such as Ivermectin vs Permethrin and Ivermectin vs Doxycycline.
Mechanism: Ivermectin acts on glutamate‑gated chloride channels; permethrin disrupts sodium channels in parasite nerve cells.
Use cases: Both treat scabies and lice; permethrin is first‑line topically, ivermectin is preferred for resistant or crusted scabies.
When ivermectin is better: Severe infestations, outbreaks, or topical treatment failure.
Mechanism: Albendazole inhibits microtubule formation; ivermectin paralyzes parasites via chloride channel activation.
Use cases: Albendazole is preferred for tapeworms and hydatid disease; ivermectin for strongyloidiasis and onchocerciasis.
When ivermectin is better: Strongyloides, onchocerciasis, resistant scabies.
Mechanism: Mebendazole blocks glucose uptake in helminths; ivermectin causes neuromuscular paralysis.
Use cases: Mebendazole is used for pinworm, whipworm, and roundworm; ivermectin for strongyloides, scabies, lice.
When ivermectin is better: Strongyloidiasis, crusted scabies, lice outbreaks.
Mechanism: Doxycycline inhibits bacterial protein synthesis; ivermectin targets parasite chloride channels.
Use cases: Doxycycline is used for acne, rosacea, and tick‑borne infections; ivermectin for parasitic infections and Demodex‑related rosacea.
When ivermectin is better: Demodex‑dominant rosacea, scabies, strongyloides.
Mechanism: Metronidazole is antimicrobial and anti‑inflammatory; ivermectin is antiparasitic with anti‑inflammatory effects.
Use cases: Both treat rosacea; metronidazole is milder, ivermectin is stronger for inflammatory lesions.
When ivermectin is better: Moderate‑to‑severe rosacea with Demodex involvement.
Mechanism: Azelaic acid reduces keratinization and inflammation; ivermectin reduces inflammation and kills Demodex mites.
Use cases: Both treat rosacea; azelaic acid is preferred for mild cases, ivermectin for inflammatory lesions.
When ivermectin is better: Papulopustular rosacea, Demodex‑associated symptoms.
| Drug | Mechanism | Primary Indications | When Ivermectin Is Preferred |
|---|---|---|---|
| Ivermectin | Glutamate‑gated chloride channel activation | Scabies, strongyloidiasis, lice, rosacea | Resistant scabies, Demodex rosacea, strongyloides |
| Permethrin | Sodium channel disruption | Scabies, lice | Crusted scabies, treatment failure |
| Albendazole | Microtubule inhibition | Tapeworms, hydatid disease | Strongyloides, onchocerciasis |
| Mebendazole | Glucose uptake inhibition | Pinworm, whipworm | Systemic parasitic infections |
| Doxycycline | Protein synthesis inhibition | Acne, rosacea, tick‑borne infections | Demodex rosacea, parasitic infections |
| Metronidazole | Antimicrobial + anti‑inflammatory | Rosacea, anaerobic infections | Moderate‑to‑severe rosacea |
| Azelaic Acid | Anti‑keratinization + anti‑inflammatory | Mild rosacea, acne | Inflammatory rosacea with Demodex |
Ivermectin has a long-established safety profile supported by decades of clinical use in both systemic and dermatologic therapy. When used at approved doses, it is generally well tolerated, with adverse effects typically mild and transient. Common reactions include dizziness, mild gastrointestinal discomfort, itching, or skin irritation. More detailed safety information is available on the dedicated page Ivermectin safety. Serious adverse events are rare and usually associated with parasite-related inflammatory responses rather than the drug itself.
Drug interactions are an important consideration, particularly for oral ivermectin. The medication is metabolized primarily through the CYP3A4 enzyme system, meaning that strong CYP3A4 inhibitors may increase systemic exposure, while inducers may reduce therapeutic levels. Additionally, ivermectin is a substrate for P-glycoprotein (P-gp), and medications that inhibit P-gp may increase penetration into the central nervous system. Clinically relevant interactions are uncommon but should be reviewed when prescribing oral ivermectin. A detailed overview is available on the page Ivermectin oral interactions.
Contraindications include known hypersensitivity to ivermectin or formulation components. Caution is advised in individuals with significant hepatic impairment due to hepatic metabolism. Oral ivermectin should be used carefully in patients taking medications that strongly affect CYP3A4 or P-gp transport. Topical ivermectin has minimal systemic absorption and therefore carries a lower risk of systemic interactions, making it suitable for long-term dermatologic use. As with any medication, ivermectin should be used under appropriate medical supervision, especially when treating systemic parasitic infections or when multiple medications are involved.
| Drug Class | Interaction Mechanism | Clinical Impact |
|---|---|---|
| CYP3A4 inhibitors | Reduced metabolism of ivermectin | Increased systemic exposure |
| CYP3A4 inducers | Accelerated metabolism | Reduced therapeutic effect |
| P-gp inhibitors | Altered drug transport across barriers | Potential CNS penetration |
| Warfarin and anticoagulants | Possible alteration of INR | Monitoring recommended |
| Other antiparasitics | Overlapping mechanisms or additive effects | Use with caution in combination therapy |
Ivermectin is generally well tolerated across oral, topical, and branded formulations, with most adverse effects being mild and transient. The safety profile is supported by decades of global use in parasitic disease control programs and dermatologic therapy. Side effects vary depending on the formulation, systemic exposure, and underlying condition. More detailed information is available on the dedicated pages: Ivermectin topical side effects and Soolantra side effects.
Oral ivermectin may cause mild dizziness, nausea, diarrhea, or fatigue. Skin itching or rash may occur, often related to parasite die‑off rather than the drug itself. In rare cases, patients with heavy parasitic loads may experience inflammatory reactions as parasites are eliminated. Serious adverse events are uncommon and typically associated with co‑infections or high parasite burden.
Topical ivermectin has minimal systemic absorption, making systemic side effects extremely rare. Local reactions may include mild burning, dryness, or irritation, especially during the first weeks of treatment. These effects usually decrease as the skin adapts. Topical formulations are considered safe for long‑term use in rosacea and Demodex‑associated conditions.
Soolantra (ivermectin 1% cream) is generally well tolerated, with adverse effects similar to generic topical ivermectin. Reported reactions include mild skin irritation, transient redness, or dryness. Cosmetic tolerability is high due to the optimized vehicle and moisturizing base.
| Form | Common Effects | Severity |
|---|---|---|
| Oral ivermectin | Dizziness, nausea, diarrhea, itching | Mild to moderate |
| Topical ivermectin | Dryness, burning, irritation | Mild |
| Soolantra | Redness, dryness, mild irritation | Mild |
The cost of ivermectin varies significantly depending on the formulation, brand, region, and availability of generics. Oral ivermectin is generally the most affordable form, widely used in global parasitic disease programs. Topical formulations, especially branded products such as Soolantra, tend to be more expensive due to specialized vehicles, dermatologic formulation standards, and market positioning. More detailed pricing information is available on the pages: Ivermectin price, Stromectol price, and Soolantra price.
Oral ivermectin tablets (3 mg or 6 mg) are typically low‑cost, especially in regions where generic versions are widely available. Prices may vary depending on pharmacy networks, insurance coverage, and national procurement programs. Stromectol, the branded oral formulation, is usually more expensive than generics.
Topical ivermectin (cream, lotion, gel) is priced higher than oral formulations due to manufacturing complexity and dermatologic formulation requirements. Generic topical ivermectin is more affordable but may vary in vehicle quality and cosmetic feel.
Soolantra (ivermectin 1% cream) is the most expensive ivermectin product due to its branded status, optimized vehicle, and strong clinical evidence in rosacea. Prices vary widely by region and may be influenced by insurance coverage, manufacturer programs, and pharmacy discounts.
Price differences across formulations reflect manufacturing costs, regulatory pathways, brand value, and therapeutic use cases. Patients often choose between branded and generic options based on affordability, tolerability, and clinical recommendations.
| Form | Typical Price Range | Notes |
|---|---|---|
| Oral ivermectin | Low | Affordable generics widely available |
| Stromectol | Medium | Higher cost due to branded status |
| Topical ivermectin | Medium to high | Varies by formulation and manufacturer |
| Soolantra | High | Premium dermatologic brand |